glucose, (beta-d)-isomer has been researched along with liraglutide in 64 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 41 (64.06) | 24.3611 |
| 2020's | 23 (35.94) | 2.80 |
| Authors | Studies |
|---|---|
| Dixon, JB | 1 |
| Bloomgarden, Z | 1 |
| Farooq, S; Islam, N; Kiran, Z; Rashid, O | 1 |
| Ingelfinger, JR; Rosen, CJ | 1 |
| Preiss, D; Sattar, N | 1 |
| Batra, M; Chaudhuri, A; Dandona, P; Garg, M; Ghanim, H; Hejna, J; Khan, S; Kuhadiya, ND; Makdissi, A; Mehta, A; Torre, B | 1 |
| Grant, PJ | 1 |
| Ceriello, A; Genovese, S; Gronda, E; Mannucci, E | 1 |
| Mudher Mikhael, E | 1 |
| Hernández, C; Simó, R | 1 |
| Schatz, H | 1 |
| Cusi, K | 1 |
| Rossello, X; Yellon, DM | 1 |
| Close, KL; Dove, AE; Gao, HX; Marathe, PH; Odeh, SA | 1 |
| Forst, T; Plum-Mörschel, L; Weber, MM | 1 |
| Fiorentino, TV; Sesti, G | 1 |
| Bell, DSH; Goncalves, E | 1 |
| Krzesinski, JM; Paquot, N; Piérard, L; Scheen, AJ | 1 |
| Bain, S; Chudleigh, RA | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N | 1 |
| Bjourson, AJ; Flatt, PR; Gault, VA; Millar, P; Moffett, RC; O'Kane, M; Parthsarathy, V; Pathak, N; Pathak, V | 1 |
| Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S; Ryder, REJ; Singh, R | 1 |
| Kaul, S | 1 |
| Ernest, P; Jandrain, B; Scheen, AJ; Wallemacq, C | 1 |
| Lovshin, JA; McReelis, KD | 1 |
| Wanner, C | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Covino, J; Hoffman, J | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Casciaro, F; Cortese, C; Cutruzzolà, A; Gnasso, A; Irace, C; Oliverio, R; Scavelli, FB | 1 |
| Leiter, LA; Lingvay, I | 1 |
| Arbel, R; Azuri, J; Hammerman, A | 1 |
| Aronson, R; Bajaj, HS; Bhullar, L; Brown, RE; Kalra, S; Sohi, N | 1 |
| Jakupović, L; Javor, E; Lucijanić, M; Lucijanić, T; Rahelić, D; Skelin, M | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Kaneko, M; Narukawa, M | 1 |
| Arena, S; Avogaro, A; Berchialla, P; Bottigliengo, D; Buzzetti, R; D'Angelo, P; Fadini, GP; Franzetti, I; Sciannameo, V; Vinci, C | 1 |
| Rothenberg, F; Schacht, S; Thompson, J | 1 |
| Bonner, C; Bousquet, C; Coddeville, A; Daoudi, M; Delalleau, N; Gmyr, V; Hubert, T; Kerr-Conte, J; Martineau, Y; Moerman, E; Pasquetti, G; Pattou, F; Quenon, A; Saponaro, C; Staels, B; Thévenet, J; Vantyghem, MC | 1 |
| Ali, SN; Dang-Tan, T; Ericsson, Å; Hansen, BB; Hunt, B; Kallenbach, K; Malkin, SJP; Valentine, WJ | 1 |
| Ambrosio, G; Anker, S; Bauersachs, J; Chioncel, O; Coats, AJS; Cosentino, F; De Boer, RA; Filippatos, G; Hill, L; Huelsmann, M; Jhund, PS; Komajda, M; Lopatin, Y; Lund, LH; Lyon, A; Metra, M; Mullens, W; Petrie, MC; Piepoli, M; Polovina, MM; Ponikowski, P; Rosano, GMC; Sari, I; Seferović, J; Seferović, PM; Thum, T; Volterrani, M | 1 |
| Kondo, Y; Konishi, H; Kyohara, M; Nakaguchi, H; Oiwa, K; Terauchi, Y | 1 |
| Andreadou, I; Balampanis, K; Bamias, A; Birba, D; Dimitriadis, G; Ikonomidis, I; Iliodromitis, E; Kalogeris, A; Katogiannis, K; Kountouri, A; Kousathana, F; Lambadiari, V; Parissis, J; Pavlidis, G; Thymis, J | 1 |
| Burren, CP; Candler, T; McGregor, D; Moudiotis, C; Narayan, K | 1 |
| Aroda, VR; Brady, EM; Davies, MJ; Gregg, EW; Khunti, K; Sargeant, JA; Tippins, F; Webb, DR; Zaccardi, F | 1 |
| Attia, SL; Mouzaki, M; Softic, S | 1 |
| Chappard, D; Gault, VA; Mabilleau, G; Mieczkowska, A; Millar, P | 1 |
| Boogerd, CJ; de Boer, RA; Dokter, MM; Lam, CSP; Markousis-Mavrogenis, G; Meems, LMG; Schouten, EM; Silljé, HHW; Voors, AA; Westenbrink, BD; Withaar, C | 1 |
| Chen, P; Jiang, J; Lin, L | 1 |
| Connelly, KA; Gordon, M; Meagher, P | 1 |
| Chen, YJ; Cheng, WL; Chung, CC; Huang, SY; Kao, YH; Lee, TI; Lee, TW; Trang, NN | 1 |
| Cessario, J; Li, Z; Pierre-Louis, V; Wahl, J | 1 |
| Baggesen, LM; Holmgaard, PH; Kahlert, J; Knudsen, JS; Lajer, M; Sørensen, HT; Thomsen, RW; Ustyugova, A; Vedin, O | 1 |
| Cui, J; Klepser, DG; McAdam-Marx, C | 1 |
| Davis, LS; Flanigan, K; Liles, JE | 1 |
| Ishihara, H; Kohno, G; Koike, M; Saito, H; Takubo, M; Watanabe, K | 1 |
| Constantino, MI; D'Souza, M; McGill, M; Middleton, TL; Twigg, SM; Wong, J; Wu, T; Yue, DK | 1 |
| Bergrath Washington, E; Brand, S; Desai, NR; Pimple, P; Reifsnider, OS; Shetty, S | 1 |
| El Medany, AMH; Ghazala, RA; Hammadi, SHM; Khalifa, HM; Zakaria Mohammed, HS | 1 |
| Bi, Y; Cheng, H; Liu, J; Miao, Y; Ni, W; Wang, J; Zhang, B; Zhang, W; Zhang, Z | 1 |
| Asseri, SM; Ebrahim, HA; El-Agawy, MSE; El-Shafey, M; El-Sherbiny, M; Eldosoky, M; Elsherbini, DMA; Elsherbiny, NM | 1 |
| Franch-Nadal, J; Gallego Estébanez, M; Hunt, B; Malkin, SJP; Martín, V; Vidal, J | 1 |
| Dai, X; Hao, H; Li, Y; Ou, T; Wang, D; Wang, R; Wang, W; Yong, H | 1 |
16 review(s) available for glucose, (beta-d)-isomer and liraglutide
| Article | Year |
|---|---|
Obesity in 2015: Advances in managing obesity.
Topics: Bariatric Surgery; Benzhydryl Compounds; Caloric Restriction; Diabetes Mellitus, Type 2; Disease Management; Exercise Therapy; Feeding Behavior; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Obesity | 2016 |
Research digest.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2016 |
Glucagon and heart in type 2 diabetes: new perspectives.
Topics: Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucosides; Heart; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Myocardium; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide-1 Receptor; Glucosides; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Peptides; Pyrrolidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Venoms; Vildagliptin | 2016 |
[Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
Topics: Benzhydryl Compounds; Cardiologists; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides | 2017 |
[Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Treatment Outcome | 2016 |
Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic | 2017 |
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 | 2018 |
Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2017 |
Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Topics: Benzhydryl Compounds; Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide | 2018 |
Oral semaglutide for the treatment of type 2 diabetes.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Sitagliptin Phosphate | 2019 |
Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Survival Rate | 2019 |
Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Topics: Adult; Benzhydryl Compounds; Chenodeoxycholic Acid; Child; Clinical Trials, Phase III as Topic; Fibroblast Growth Factors; Glucosides; Humans; Imidazoles; Isobutyrates; Liraglutide; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Oxazoles; Polyethylene Glycols; Pyridazines; Pyrimidines; Severity of Illness Index; Sulfoxides; Treatment Outcome; Uracil | 2021 |
6 trial(s) available for glucose, (beta-d)-isomer and liraglutide
| Article | Year |
|---|---|
Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Prognosis; Young Adult | 2016 |
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatme
Topics: Adult; Aged; Arterial Pressure; Arteries; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelial Cells; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycocalyx; Greece; Humans; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Ventricular Function, Left | 2020 |
Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Incretins; Liraglutide; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Improving beta-cell secretory function and glycaemia in young-onset type 2 diabetes: A pilot, 12-month, randomized trial of a novel, continuous glucose monitor-guided, rapid treatment intensification strategy incorporating empagliflozin and liraglutide.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2022 |
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Topics: Acarbose; Benzhydryl Compounds; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin | 2022 |
Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Glycolipids; Humans; Liraglutide; Metabolic Syndrome; Quality of Life; Stroke Volume; Uric Acid; Ventricular Function, Left | 2022 |
42 other study(ies) available for glucose, (beta-d)-isomer and liraglutide
| Article | Year |
|---|---|
Glycemic control and the heart: it matters how you get there.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Outcome Assessment, Health Care; Pioglitazone; Thiazolidinediones | 2016 |
Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male | 2016 |
London buses: A cardiovascular outcome trial equivalent?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Protective Factors; Risk Factors; Treatment Outcome | 2016 |
New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Topics: Adamantane; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Peptides; Piperidines; Risk; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Uracil | 2016 |
After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Liraglutide | 2016 |
Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2016 |
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2017 |
Obesity Week 2016 Annual Meeting.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prediabetic State; Quality of Life; Treatment Outcome; Weight Loss | 2017 |
[Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cardiovascular System; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors | 2016 |
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
Topics: Aged; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Interleukin-6; Liraglutide; Male; Mice; Neurons; Neuroprotective Agents | 2017 |
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Thiazolidinediones; Treatment Outcome | 2017 |
[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Kidney Diseases; Liraglutide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
[SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?
Topics: Benzhydryl Compounds; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Risk Factors | 2018 |
Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.
Topics: Aged; Benzhydryl Compounds; Blood Viscosity; Carotid Artery, Common; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Incretins; Liraglutide; Male; Middle Aged; Prospective Studies; Regional Blood Flow; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Stress, Mechanical; Time Factors; Treatment Outcome | 2018 |
Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide | 2018 |
Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Costs; Female; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Benzhydryl Compounds; Canada; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Registries; Retrospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2019 |
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Glucagon; Glucosides; Humans; Liraglutide; Male; Mice; Somatostatin | 2019 |
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Topics: Benzhydryl Compounds; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Middle Aged; Sitagliptin Phosphate; United States; Weight Loss | 2019 |
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Topics: Benzhydryl Compounds; Canagliflozin; Cardiology; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Europe; Glucagon-Like Peptide-1 Receptor; Glucose; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Liraglutide; Societies, Medical; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2020 |
Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.
Topics: Adolescent; Benzhydryl Compounds; Blood Glucose; Child; Diabetes Mellitus; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Liraglutide; Prader-Willi Syndrome; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Middle Aged; Sitagliptin Phosphate; Young Adult | 2020 |
Dapagliflozin and Liraglutide Therapies Rapidly Enhanced Bone Material Properties and Matrix Biomechanics at Bone Formation Site in a Type 2 Diabetic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Biomechanical Phenomena; Bone Density; Bone Matrix; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Liraglutide; Mice; Osteogenesis | 2020 |
The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
Topics: Angiotensin II; Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Female; Fibrosis; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Glucosides; Heart Failure, Diastolic; Hypertrophy, Left Ventricular; Incretins; Liraglutide; Mice, Inbred C57BL; Myocardium; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
Topics: Animals; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Inflammasomes; Liraglutide; Male; NLR Family, Pyrin Domain-Containing 3 Protein; Rats; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Biomarkers; Cytokines; Diabetic Cardiomyopathies; Disease Models, Animal; Echocardiography; Energy Metabolism; Fatty Acids; Fibrosis; Glucose; Glucosides; Heart Function Tests; Hypoglycemic Agents; Immunohistochemistry; Inflammation Mediators; Liraglutide; Myocardium; Rats; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cell Death; Cells, Cultured; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Topics: Acute Disease; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Hospitalization; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Population Surveillance; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Survival Rate; Treatment Outcome | 2021 |
Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States.
Topics: Administration, Oral; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Sitagliptin Phosphate; United States | 2021 |
Association of IL-17 Inhibitor and SGLT2 Inhibitor with Candida Pyelonephritis.
Topics: Antibodies, Monoclonal, Humanized; Benzhydryl Compounds; Candida glabrata; Candidiasis, Invasive; Dermatologic Agents; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin Detemir; Liraglutide; Middle Aged; Psoriasis; Pyelonephritis; Recurrence; Sepsis; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections | 2021 |
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Hypoglycemic Agents; Insulin-Secreting Cells; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Prospective Studies; United States | 2022 |
The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model.
Topics: Animals; Atorvastatin; Benzhydryl Compounds; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Liraglutide; Male; Pyrroles; Rats; Thyrotropin | 2022 |
Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Glucosides; Humans; Inflammation; Liraglutide; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Topics: Administration, Oral; Benzhydryl Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Sitagliptin Phosphate; Spain | 2022 |